A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer

Hozhabri, Hossein; Moghaddam, Marziyeh Mazaheri; Moghaddam, Madiheh Mazaheri; Mohammadian, Ali

doi:10.1038/s41598-022-14610-2

Cited by 11 publications

(41 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we found that ZNF639 knockdown increased the expression of CCL20 and downstream phosphorylation of AKT and STAT3. CCL20 is one of the C-C and C-X-C chemokines that correlate with the clinical outcomes of breast cancer patients [22]. Our ndings are in agreement with others showing that CCL20 induces epithelial-mesenchymal transition with upregulation of vimentin and Snail1 in breast epithelial cells through the PI3K/AKT and JAK2/STAT3 pathways [23,24].…”

Section: Discussionsupporting

confidence: 91%

Zinc finger protein 639 expression is a novel prognostic determinant in breast cancer

Lee,

Cheng,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: ZNF639 is often contained within the overlapping amplicon of PIK3CA, and previous studies suggest that it was involved in the pathogenesis of esophageal and oral squamous cell carcinomas. However, its expression and significance in breast cancer remain uncharacterized. Methods: Immunohistochemical analysis of ZNF639 was performed on our tissue microarrays. Functional studies including colony formation, transwell cell migration, and in vivo metastasis were performed in breast tumor cells with ZNF639 knockdown by siRNA transfection. Results: Reduced ZNF639 immunoreactivity was observed in 82% of breast cancer samples independent of hormone receptor and HER2 status. In multivariate Cox regression analyses, ZNF639 expression was negatively associated with recurrence-free survival (hazard ratio = 0.36) and marginally with overall survival (hazard ratio = 0.42). ZNF639 knockdown increased clonogenicity, cell motility, and murine lung metastasis. Snail1, vimentin, and CCL20 expression were upregulated following ZNF639 knockdown, and ZNF639-mediated changes in cell phenotype were neutralized by CCL20 double-knockdown. Conclusion: Low ZNF639 expression represents a novel prognostic factor for recurrence-free survival in patients with breast cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Zinc finger protein 639 expression is a novel prognostic determinant in breast cancer

Lee,

Cheng,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…CXCL9 has been proved to be a good prognostic biomarker for many tumors. Hozhabri et al found higher levels of CXCL9 in breast cancer patients with higher SBR grade; furthermore, high CXCL9 expression levels were signi cantly associated with lymphocytic in ltration and better response to chemotherapy in breast cancer patients [32] . In the present study, a joint database analysis showed that CXCL9 presented high expression in EC.…”

Section: Discussionmentioning

confidence: 98%

High expression of CXCL9 gene promotes immune invasion and improves the prognosis of patients with endometrial cancer

Zhang¹,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: CXCL9 plays a key role in immune cell chemotaxis and inhibition of tumor angiogenesis. The aim of this study was to investigate the prognostic value of CXCL9 in endometrial cancer (EC) and the impact on the immune microenvironment. Methods：RNA sequencing data for EC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, while clinicopathological information for EC patients was obtained from the TCGA database. Cox univariate and multivariate analyses were used, followed by the construction and validation of nomograms. CXCL9 expression and survival analysis, gene correlation and immune infiltration correlation analysis, and pathway enrichment analysis were performed using UALCAN, Kaplan-Meier, GeneMANIA, STRING, TIMER, cBioPortal, muTarget, CIBERSORT, TISIDB, GO, KEGG and GSEA tools. Results：CXCL9 was significantly upregulated in EC. Cox univariate and multivariate analysis showed that CXCL9 was an independent predictor of overall survival (OS), disease specific survival (DSS) and progression free interval (PFI) (P<0.05). However, increased CXCL9 expression predicted prolonged OS, DSS and PFI (P<0.05). In addition, CXCL9 was positively correlated with immune cell infiltration and correlated with marker genes of multiple immune pathways as well as marker genes of immune checkpoints. GSEA enrichment analysis suggests that high CXCL9 expression plays an important role in immune cell migration, activation and other functions. Conclusion: The results of this study suggest that high CXCL9 expression was a predictor of good prognosis in patients with EC and may be associated with the recruitment of immune cells to the tumor microenvironment in the tumor tissue to function as an anti-tumor immune response.

show abstract

“…-In the triple-negative (TNBC) subtype of breast cancer, higher levels of CCL5 than in non-TNBC are pointed out (Hozhabri, Moghaddam, Moghaddam, & Mohammadian, 2022).…”

Section: C-c Motif Chemokine Ligand 5 (Ccl5)mentioning

confidence: 99%

“…Chen et al, 2020). A shorter OS and RFS are recorded in low-expressed CCL21 BC patients, which is proposed to increase immunogenicity (Hozhabri et al, 2022). In conjunction with CCL19, CCL21 is documented to take a vital part in establishing a bridge between dendritic cells and naïve T cells and activates TH1-polarized immunogenicity (Nguyen-Hoai et al, 2016).…”

Section: C-c Motif Chemokine Ligand 21 (Ccl21)mentioning

confidence: 99%

See 1 more Smart Citation

Chemokine Signaling in Breast Cancer: Focus on Cc-Motif Chemokine Ligands

Kacar

2024

Preprint

View full text Add to dashboard Cite

Based on 2020 data from GLOBOCAN, breast cancer holds the highest incidence rate in the majority of countries (159 out of 185 countries) and is the leading cause of mortality in 110 countries Chemokines are 8-10 kDa proteins activating through transmembrane G-coupled receptors (GPCRs) with 24 CC-motif type known human cytokines and 10 respective receptors. Chemokines and chemokines receptors have the potential for new breast cancer therapeutics modalities. In the complex chemokine world, not only one chemokine can bind to multiple receptors but also one receptor can be activated by several chemokine ligands. The fact that immune cells possess the potential to express multiple receptors and also secrete a diverse number of chemokines further intensifies the intricate and challenging to grasp chemokines interaction with receptors and microenvironment. In addition, the implication of chemokines in the malignant activation of tumor cells makes them indispensable contributors to the cancer microenvironment and influences the fate of tumor cells and the overall survival of the patients. Therefore, herein, we aimed in this study at attracting the researchers attention to the particular function of all known CC-motif chemokines and to-date findings, their expressional changes in normal, tumor and tumor adjacent tissues, important key effects in breast cancer and more importantly, we analyzed the expression data breast tumor samples retrieved from TCGA, Xena UCSC as well as UALCAN database regarding to showing any potential to be a general, subclass-specific or stage-specific marker as well as effects of overall survival of the patients and their correlation with literature findings. Basically, we desire this study to be a sort of reference insight for effects of human CC-motif chemokines in breast cancer or provide ready-to-use source and insights for researchers with the graphs and analyzes from different databases.

show abstract

A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer

Cited by 11 publications

References 101 publications

Zinc finger protein 639 expression is a novel prognostic determinant in breast cancer

Zinc finger protein 639 expression is a novel prognostic determinant in breast cancer

High expression of CXCL9 gene promotes immune invasion and improves the prognosis of patients with endometrial cancer

Chemokine Signaling in Breast Cancer: Focus on Cc-Motif Chemokine Ligands

Contact Info

Product

Resources

About